精達股份(600577.SH):參股公司首次公開發行股票並在科創板上市申請獲上交所受理
格隆匯6月18日丨精達股份(600577.SH)公佈,公司參股公司上海超導科技股份有限公司(以下簡稱“上海超導”)首次公開發行股票並在科創板上市申請於2025年6月18日獲得上海證券交易所(以下簡稱“上交所”)受理。
上海超導是一家專注於高溫超導材料研發、生產和銷售的高新技術企業,是國際上唯二已經實現批量年產千公里級以上(12mm寬)第二代高溫超導帶材的生產商之一。截至本公告披露日,公司持有上海超導9,458.75萬股,持股比例爲18.15%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.